The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1643
February 7, 2022
View Complete Issue         Table of Contents 2019 
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
February 7, 2022 (Issue: 1643)
The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
Article code: 1643a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.